PYXSPyxis OncologyPYXS info
$3.78info3.28%24h
Global rank18410
Market cap$167.54M
Change 7d0.93%
YTD Performance111.17%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Pyxis Oncology (PYXS) Stock Overview

    Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

    PYXS Stock Information

    Symbol
    PYXS
    Address
    150 Cambridgepark DriveCambridge, MA 02140United States
    Founded
    -
    Trading hours
    9:30 AM - 4:00 PM ET
    Website
    https://pyxisoncology.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    617 221 9059

    Pyxis Oncology (PYXS) Price Chart

    -
    Value:-

    Pyxis Oncology Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $3.78
    N/A
    Market Cap
    $167.54M
    N/A
    Shares Outstanding
    44.32M
    N/A
    Employees
    67.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org